ABBI LAMPARELLI: Open Payments
NPI 1255103172 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$474 in 21 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $118 · 2025 $474
Food & beverage: $474
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $147 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $90 |
| Madrigal Pharmaceuticals | 3 | $90 |
| Optinose US, Inc. | 2 | $51 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
| Novo Nordisk Inc | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $19 |
| QOL Medical, LLC | 1 | $14 |
Products named: XIFAXAN, REZDIFFRA, CREON, LINZESS, Xhance, IQIRVO, Wegovy, ENTYVIO.
Industry payments across MD — which companies pay providers there.
